Skip to content

Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence

Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02143505
Enrollment
900
Registered
2014-05-21
Start date
2014-03-31
Completion date
2019-02-28
Last updated
2014-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenoma

Brief summary

Calcium plus vitamin D may be effective in the prevention of colorectal adenoma recurrence. The aim of this study is to investigate the effect of supplementation with calcium plus vitamin D on the recurrence of colorectal adenomas.

Detailed description

Colorectal adenomas are well-known to be precancerous lesions that develop into colorectal cancers on the basis of the adenoma-carcinoma sequence. The effects of screening for colorectal adenomas and removing precancerous lesions on the prevention of colorectal cancer have been established. Because of the high recurrence rates of colorectal adenomas in patients who have undergone polypectomy, the potential chemopreventive agents that may reduce the risk of colorectal adenoma recurrence need to be investigated. Since laboratory and epidemiologic evidence suggests that calcium or vitamin D may help prevent colorectal adenomas, we conduct a randomized, placebo-controlled, prospective clinical trial to study the effect and safety of calcium plus vitamin D supplementation in prevention of colorectal adenomas recurrence.

Interventions

DRUGCa plus vit D

elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements

Sponsors

Ministry of Science and Technology of the People´s Republic of China
CollaboratorOTHER_GOV
Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Individuals aged 18-65years * Individuals who had at least one histologically confirmed colorectal adenoma removed within three months before recruitment * Individuals without a history of familial polyposis * Those who voluntarily sign the consent form after being fully informed and understanding the purpose and procedures of the study , characters of the disease, effect of medications, methods of related examinations, and potential risk/benefits of the study

Exclusion criteria

* Patients who are hypersensitive or intolerant to the drugs * Patients who are intolerant to another colonoscopy examination * Patients with hypercalcemia or urolithiasis * Pregnant women, women during breast-feeding period, or women with expect pregnancy * Patients with diabetes mellitus, severe heart or renal disease, or cancer history * Patients with a history of subtotal gastrectomy or partial bowel resection * Patients who are not able to cooperate * Individual who are involved in designing, planning or performing this clinical trial * Patients with medical conditions who are not appropriate to participate the study * Patients who are taking aspirin, NSAIDs or COX2 inhibitors * Patients who are taking folic acid or Butyrate. * Patients with IBD

Design outcomes

Primary

MeasureTime frame
The primary objective of this study is to investigate recurrence rates of colorectal adenoma (CRA) after calcium plus vitamin D intervention.3 years

Secondary

MeasureTime frame
The recurrence rates of advanced colorectal adenoma (A-CRA) after calcium plus vitamin D intervention.3 years

Other

MeasureTime frame
the incidence of colorectal cancer (CRC) after calcium plus vitamin D intervention3 years
changes in clinical symptoms scores (positive iFOBT, diarrhea, or constipation et al)baseline and 3 years
changes in serum calciumbaseline and 3 years
changes in routine blood count, urine and stool routine test, liver and kidney functions, etcbaseline and 3 years
differences in the number, location, size and histological subtype of CRAbaseline and 3 years
changes in serum 25-(OH) Vit D levelbaseline and 3 years

Countries

China

Contacts

Primary ContactJing-Yuan Fang, M.D., Ph.D
fangjingyuan_new@163.com86-21-53882450
Backup ContactYing-Xuan Chen, M.D., Ph.D
yingxuanchen71@126.com86-21-63200874

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026